GlobeImmune, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBIM research report →
Price Chart
About the company
GlobeImmune, Inc. , a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases.
- CEO
- Donald Bellgrau
- IPO
- 2014
- Employees
- 2
- HQ
- Louisville, CO, US
Get TickerSpark's AI analysis on GBIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $575
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 3.84
- Div Yield
- 0.00%
- Gross Margin
- 58.99%
- Op Margin
- -42.85%
- Net Margin
- -42.85%
- ROE
- -64.41%
- ROIC
- -38.00%
Latest fiscal year · YoY change
- Revenue
- $6.46M+8.2%
- Gross Profit
- $3.81M+291.1%
- Op Income
- $-2,766,905
- Net Income
- $-2,766,905+86.3%
- EPS
- $-0.48+93.1%
- OCF Growth
- +29.1%
- FCF Growth
- +30.7%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.93
- RSI (14)
- 52
- Avg Volume
- 841
No earnings-call transcripts are available for GBIM yet.
- Free Float
- 76.0%
- Shares Outstanding
- 5.75M
- Float Shares
- 4.37M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ubs AG | 551 | ▲ 551 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 16 | Torres S. Edward | sell | 26,188 |
| Mar 18, 16 | LAWLOR AUGUSTINE | sell | 11,000 |
| Mar 16, 16 | MITCHELL DANIEL J | sell | 8,862 |
| Mar 17, 16 | MITCHELL DANIEL J | sell | 12,468 |
| Mar 16, 16 | MITCHELL DANIEL J | sell | 112 |
| Mar 17, 16 | MITCHELL DANIEL J | sell | 158 |
| Mar 15, 16 | LAWLOR AUGUSTINE | sell | 2,500 |
| Mar 11, 16 | MITCHELL DANIEL J | sell | 76,662 |
| Mar 15, 16 | MITCHELL DANIEL J | sell | 50,831 |
| Mar 11, 16 | MITCHELL DANIEL J | sell | 2,131 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GBIM coverage
Recent articles, reports, and earnings notes.
No research on GBIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBIM report →